With extensive experience in the healthcare industry, Alexander Cherkassky began his career as ab organic laboratory supervisor at Thermo Fisher Scientific in Massachusetts. Here, he was in charge of scheduling personnel and workflow, as well as overseeing sample analysis and quality control in accordance with US EPA regulations. Since 2018, Alexander Cherkassky has served as the senior director of the national mass cytometry and spatial tissue imaging franchise of San Francisco’s Fluidigm.
On Tuesday, September 28, Fluidigm Corporation, an advanced biotechnology tools supplier with a mission to enhance the quality of living via complete health insight, announced a partnership agreement with the Karolinska Institutet for research and product development using CyTOF® XT. The fourth-generation CyTOF XT platform is based on Fluidigm’s groundbreaking CyTOF technology. The partnership will focus on CyTOF-based research in the Institute’s Women’s and Children’s Health Department.
CyTOF XT™ was launched to make deep cell profiling studies easier for researchers, standardize sample analysis with repeatable processes and automation, and also speed up the development of innovative therapies. Translational and clinical researchers in the pharmaceutical and biotechnology industries, as well as contract research firms that service them, can all benefit from CyTOF XT.
Fluidigm President and CEO Chris Linthwaite stated, “Collaborating with one of the world’s most prestigious medical universities is an honor for Fluidigm, and we are excited to partner with Karolinska Institutet.” The Karolinska Institutet is one of the world’s leading medical institutions and Sweden’s biggest single academic medical research facility. It is situated in Stockholm.
Alexander Cherkassky 